MDM2 and neoplasm: Therefore, inhibition of MDM2-p53 binding is an attractive target for restoration of p53 activity in tumor cells, and small-molecule MDM2 inhibitors have shown promise in previous preclinical studies [23, 24] and in the present work (Figure 3B and Figure S2).